We serve 4-Chloro-3-nitroquinoline CAS:39061-97-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 4-Chloro-3-nitroquinoline
CAS.NO: 39061-97-7
Synonyms:
3-Nitro-4-chloroquinoline
4-Chloro-3-nitroqulinoline
4-chloro-3-nitro-quinoline
4-Chlor-3-nitro-chinolin
QUINOLINE,4-CHLORO-3-NITRO
4-Chloro-3-Nitroquinoline
Molecular Formula: C9H5ClN2O2
Molecular Weight: 208.60100
Physical and Chemical Properties:
Density: 1.484 g / cm3
Boiling point: 333.8ºC at 760 mmHg
Melting point: 121-122 ° C
Flash point: 155.7ºC
Refractive index: 1.688
Specification:
Appearance:White to off-white crystalline powder
Purity:≥98.0%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:
Intermediates of Imiquimod CAS:99011-02-6.
Contact us for information like 4-Chloro-3-nitroquinoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Chloro-3-Nitroquinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Nitro-4-chloroquinoline Use and application,3-Nitro-4-chloroquinoline technical grade,usp/ep/jp grade.
Related News: Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.(2R,3R,4S,5R)-2-(6-amino-2-iodopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol manufacturer Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.1-Bromo-7-chloroheptane supplier AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer.Ethyl 4,6-dichloropyridazine-3-carboxylate vendor Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.
